{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-046101","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.258295+00:00","generated_at":"2026-05-22T03:48:23.901058+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Iovance Q1 2025 revenue $49.3M; FY2025 guidance revised to $250-300M","bullets":["Q1 2025 product revenue $49.3M from Amtagvi ($43.6M) and Proleukin ($5.7M); net loss $116.2M ($0.36 diluted).","FY2025 total product revenue guidance revised to $250-300M reflecting launch dynamics and ATC growth trajectories.","Cash and investments $366M as of March 31, 2025; expected to fund operations into second half of 2026.","Q1 manufacturing capacity reduced by annual maintenance; fully resumed, targeting 100-110 commercial infusions in Q2.","On track for Amtagvi regulatory approvals in UK, EU, Canada in 2025; NSCLC registrational data in 2H25."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-046101","json":"https://secwatch.observer/filing/0001104659-25-046101.json","markdown":"https://secwatch.observer/filing/0001104659-25-046101.md","text":"https://secwatch.observer/filing/0001104659-25-046101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465925046101/0001104659-25-046101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465925046101/tm2514273d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T03:48:23.901058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}